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pneumoniae may be involved as an initiating or accelerating
agent in the process leading to aneurysm formation and
expansion.5,6 Elastolytic matrix metalloproteinases (MMPs)
have been identified as being involved in the development of
AAA, and they may provide useful targets for medical treat-
ment of small aneurysm.7 Kol et al8 have shown in human
atherosclerotic arteries that chlamydiae induce the produc-
tion of MMPs by macrophages, and this process is mediated
by chlamydial heat shock protein 60.
Doxycycline has been shown in several experimental
studies to inhibit MMP activity and elastin degradation
of the aortic wall, thus suggesting its potential role in
reducing the growth rate of AAA.7,9,10 Because doxycy-
cline is effective in the management of C pneumoniae
infection as well, it may provide a double-edged sword in
altering the process of aneurysmal degeneration and
dilatation. However, there are no clinical data supporting
any potential role of doxycycline in the management of
small AAA.
We designed this pilot prospective, double-blind, ran-
domized, placebo-controlled study to investigate the effi-
cacy of doxycycline in reducing the expansion of small,
asymptomatic AAAs.
Patients with abdominal aortic aneurysms (AAAs)
larger than 5 cm have a risk of rupture of 25% within 5
years with high morbidity and mortality rates.1 Elective
repair of the aneurysm with either open or endovascular
techniques is therefore advocated in these patients to
reduce the need for emergency surgery, but these treat-
ment methods are still associated with significant morbid-
ity and mortality rates. There are a large number of
patients with small AAAs who are not candidates for open
or endoluminal repair and who would benefit from a treat-
ment other than watchful waiting.1-3
Chronic inflammation is considered to be a contributing
factor in the pathogenesis of aneurysm,4 and Chlamydia
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Objective: Eradication of Chlamydia pneumoniae infection and inhibition of elastolytic matrix metalloproteinases with
doxycycline have been suggested to reduce the growth rates of small abdominal aortic aneurysms (AAA). We designed
a study to investigate the efficacy of doxycycline in reducing the expansion of small AAAs.
Subjects and Methods: This was a prospective, double-blind, randomized, placebo-controlled study that was set in a uni-
versity referral hospital. The study group consisted of 32 of 34 initially eligible patients who had an AAA diameter per-
pendicular to the aortic axis of 30 mm or more in size or a ratio of infrarenal to suprarenal aortic diameter of 1.2 or
more and a diameter less than 55 mm. Patients were randomly assigned to receive either doxycycline (150 mg daily) or
placebo during a 3-month period and underwent ultrasound surveillance during an 18-month period. Outcome mea-
sures included aneurysm expansion rates, the number of patients who had AAA rupture or repair, C pneumoniae anti-
body titers, and serum concentrations of C-reactive protein.
Results: The aneurysm expansion rate in the doxycycline group was significantly lower than that in the placebo group
during the 6- to 12-month (P = .01) and the 12- to 18-month periods (P = .01). Five patients (41%) in the placebo
group and 1 patient (7%) in the doxycycline group had an overall expansion of the aneurysm of 5 mm or more during
the 18-month follow-up. Among the placebo group patients, a higher expansion rate was observed in those with
enhanced C pneumoniae immunoglobulin G antibody titers (> 128) than in those with lower titers (P = .03).
Doxycycline treatment had no clear effect on antibody titers. However, at 6-month follow-up, C-reactive protein lev-
els in the doxycycline group were significantly lower than the baseline levels (P = .01).
Conclusions: The results of this small pilot study suggest that doxycycline may favorably alter the outcome of patients
with small AAA. However, because of the small size of this randomized study and of the potentially confounding effect
of pretreatment risk factors, doxycycline-based treatment cannot be justified only on the ground of the current results.
Because of the high prevalence of this disorder and its clinical, social, and economic relevance, a multicenter study
should be performed to further investigate whether there is any place for medical treatment of small AAAs. (J Vasc
Surg 2001;34:606-10.)
METHODS
Consecutive patients with an asymptomatic infrarenal
AAA were recruited between January 1997 and February
1998 at the Department of Surgery of the Oulu
University Hospital, Oulu, Finland. Eligible patients were
those with an aneurysm diameter perpendicular to the aor-
tic axis of 30 mm or more in size or a ratio of infrarenal to
suprarenal aortic diameter of 1.2 or more and a diameter
less than 55 mm. One patient with a 20-mm saccular AAA
was included in the study as well.
The institutional ethics committee approved the study
protocol, and all patients gave written informed consent
before enrollment in the study.
Patients were randomly assigned at the initial visit to
receive either doxycycline (150 mg daily, tablets) or an
identical-appearing placebo during a 3-month period.
Study drugs were randomly assigned numbers in blocks,
and the treatment assignments were unavailable to either
the investigators or the patients during the trial.
Randomization was conducted by the firm that pro-
vided doxycycline and placebo tablets.
C pneumoniae–specific serum immunoglobulin (Ig) G
and IgA antibodies were determined by the microim-
munofluorescence method using strain Kajaani 6 elemen-
tary bodies as antigen and fluorescein isothiocyanate
conjugated antihuman IgG (Kallestad, Austin, Tex) and
IgA (Sigma, St Louis, Mo) antibodies. The antibody
determinations of each case and the individual control
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were always tested simultaneously in the same titration
series in a blinded fashion. The antibody determinations
were done from sera collected at the beginning of the
study and at 6-month and 12-month intervals. C-reactive
protein (CRP) was measured from the same sera with a
rapid (15 minutes) two-site ultrasensitive assay11 in the
form of prototype reagents from InnoTrac Diagnostics Oy
(Turku, Finland). The dynamic range is from 0.1 to 300
mg/L with a within-assay coefficient of variation of less
than 6% over the whole range.
Ultrasonographic measurements were performed by
one senior radiologist with special interest in vascular
ultrasonography using one ultrasound machine. The
abdominal aorta was examined along its entire length, and
the largest diameter, anteroposterior or transverse, was
used. Ultrasonography was performed every 6 months,
and patients were followed up for as much as 18 months.
Inclusion in the study required a follow-up of at least 6
months and two or more ultrasonographic examinations.
Each patient was followed up with until the patient’s
death, elective or emergency repair of the aneurysm, or
abdominal surgery for other diseases.
Statistical analysis was performed with the statistical
database SPSS for Windows 9.0 (SPSS Inc, Chicago, Ill).
The Fisher exact test and the Mann-Whitney test were used
to analyze differences between groups. Pearson correlation
coefficients were calculated to analyze the correlation
between continuous variables. One-way analysis of variance
with the Bonferroni multiple comparison test was used to
Table I. Characteristics of patients
Doxycycline group (n = 17) Placebo group (n = 15) P value
Sex (male/female) 16/1 13/2 NS
Age (y)* 68.6 (64.4-71.3) 68.1 (64.1-73.0) NS
Diabetes 4 (23.5%) 1 (6.6%) NS
Hypertension 8 (47.0%) 5 (33.3%) NS
β-Blockers 11 (64.7%) 7 (46.6%) NS
Smoking 3 (17.6%) 8 (53.3%) NS
COPD 2 (11.7%) 4 (26.6%) NS
*Values are shown as medians and 25th and 75th interquartile ranges.
Table II. Follow-up data*
Doxycycline group Placebo group P value
Size of the aneurysm (mm)
At baseline 31.0 (27.5-38.5) 35.0 (31.0-40.0) NS
At 6 mo 32.0 (27.5-39.0) 36.0 (32.0-40.0) NS
At 12 mo 33.0 (26.7-38.7) 39.0 (33.7-44.5) .06
At 18 mo 33.0 (26.7-38.5) 39.0 (30.5-44.0) NS
Expansion rate (mm/y)
During 0- to 6-mo period 0.0 (0.0-2.0) 0.0 (0.0-2.0) NS
During 6- to 12-mo period 0.0 (0.0-2.0) 2.0 (2.0-6.5) .01
During 12- to 18-mo period 0.0 (0.0-1.0) 5.0 (2.5-12.0) .01
During 0- to 18-mo period (mm) 1.5 (0.0-3.0) 3.0 (0.25-6.0) NS
*Values are shown as medians and 25th and 75th interquartile ranges.
evaluate differences in aneurysm growth rate at different
intervals in patients with chronic obstructive pulmonary
disease (COPD) and/or a smoking habit receiving or not
receiving β-blockers and in patients without COPD or
smoking habit. The repeated CRP measurements were
individually contrasted with baseline levels. A P value less
than .05 was considered statistically significant.
RESULTS
The study population consisted of 34 patients. Two
patients were excluded from the study because one died
and another underwent emergency operation for colon
perforation shortly after the beginning of the study.
Therefore, analysis involved 32 patients, 17 in the doxycy-
cline-treated group and 15 in the placebo group.
The patients’ data are shown in Table I. Although
there were some differences in the status of diabetes,
hypertension, COPD, smoking, and use of β-blockers
between the study groups, these differences were not sta-
tistically significant (Table I).
The numbers of patients who underwent 6-month,
12-month, and 18-month ultrasound scanning were 32,
24, and 26, respectively. The median follow-up was 18
months. The prevalence of patients with elevated C pneu-
moniae–specific IgG (≥ 128) and IgA (≥ 64) antibodies at
the beginning of the study was 52.9% and 23.5% in the
doxycycline group, respectively, and 46.7% and 46.7% in
the placebo group, respectively (P = not significant [NS]).
The medication was well tolerated in all but two
patients, one in the control group and one in the doxycy-
cline group, who had to discontinue the drug treatment
after about 2 months because of allergic reaction.
The overall aneurysm expansion rates during the 18-
month follow-up were higher in the placebo group (3.0
mm) than in the doxycycline group (1.5 mm) (Table II), but
the difference did not reach statistical significance. The
median aneurysm expansion rate in the doxycycline-treated
group was significantly lower than in the placebo group dur-
ing the 6- to 12-month period (P = .01), and the 12- to 18-
month period (P = .01) (Table II). Five patients (41%) in the
placebo group and one patient (7%) in the doxycycline
group had an overall expansion of the aneurysm of 5 mm or
more during the 18-month follow-up (P = .06) (Figure).
There was a correlation between the baseline diameter
of the aneurysm and the overall expansion during the 18-
month period (P = .01), but there was no correlation
between the baseline aneurysm diameter and the expansion
rates of the aneurysms during all of the 6-month intervals.
Patients with COPD and/or smoking habit and
receiving β-blockers had a median overall aneurysm
growth of 3 mm (range, 1-8 mm), patients with COPD
and/or smoking habit not “counteracted” by the use of β-
blockers had a median overall aneurysm growth of 1 mm
(range, 1-6 mm), and patients without COPD or smoking
habit had a median overall aneurysm growth of 1 mm
(range, 1-6 mm) (P = NS). No statistically significant dif-
ferent growth rates were observed at different 6-month
intervals as well.
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At 6-month and 12-month intervals, there was no sta-
tistically significant difference in the C pneumoniae titers
in either group. However, among placebo group patients,
the expansion rate was significantly higher in patients with
high titers of C pneumoniae–specific IgG (≥ 128) than in
those with lower titers (3.75 mm vs 0.89 mm, P = .03),
whereas such a difference in the expansion rate was not
statistically significant in the doxycycline-treated group
(1.78 mm vs 0.78 mm).
Mean CRP values in doxycycline and placebo groups
at baseline were 6.47 mg/L and 3.77 mg/L and at 6-
month follow-up were 3.80 mg/L and 5.66 mg/L,
respectively. When the CRP values at the 6-month follow-
up visit were contrasted to baseline levels, the mean
decrease was 3.1 mg/L in the doxycycline group, whereas
in the placebo group the CRP levels rose with a mean
increase of 1.9 mg/L (P = .01).
During the 18-month follow-up period, 4 patients, 3
in the placebo group and 1 in the doxycycline-treated
group, died of causes unrelated to the aneurysm.
One patient in the doxycycline-treated group under-
went emergency operation for rupture of a 40-mm
aneurysm. Three patients in the placebo group and one in
the doxycycline-treated group underwent elective repair
of the AAA. This was accomplished through open surgery
in three cases and endoluminal stent-grafting in one case.
After the end of the study, three other patients in the
placebo group and one other patient in the doxycycline-
treated group underwent elective open repair of the
aneurysm.
DISCUSSION
Current experience suggests that AAAs of less than 5.5
cm in diameter should be followed up with serial ultra-
sound scans, and there is indication for elective repair
when the growth rate is more than 1 cm per year or the
aneurysm is larger than 5.5 cm.2 However, this policy of
Scatterplot showing overall expansion of aneurysms during 18-
month follow-up period.
watchful waiting must be faced with the patient’s fear of
rupture and likely death12 and with a reported annual
mortality rate of 7.4% for patients undergoing a surveil-
lance program for AAAs ranging in size from 4 to 5.5 cm.2
Early surgical repair does not seem to reduce these mor-
tality rates2; therefore, a medical treatment is advocated to
limit the expansion of small AAAs and reduce the risk of
aneurysm rupture and the need for emergency and elective
operations with their associated morbidity and mortality.
This therapy would certainly also be useful in the manage-
ment of dilatation of the proximal neck and aneurysm sac
observed in a conspicuous number of patients after
endovascular stent grafting repair.13-15
There is some evidence that nonsmokers16,17 and
patients receiving β-adrenergic blockade18,19 have lower
AAA growth rates. Discouraging smoking is of key impor-
tance in this patient population, but its impact in reducing
the aneurysm growth rate is not clear, whereas β-blockers
failed to achieve a place in the conservative management
of small AAAs.20 New insights in the knowledge of cellu-
lar and molecular events underlying aneurysmal degenera-
tion suggest that eradication of C pneumoniae infection
and inhibition of MMPs with doxycycline may be useful in
the management of this disease.6,8,21,22 Several experi-
mental studies confirmed that doxycycline effectively
reduces the progressive elastic fiber degradation of the
aortic wall and aneurysm expansion.7,9,21,22 The influence
of doxycycline on aortic wall expression and activity of
MMPs has been shown even in aneurysm wall specimens
of patients treated preoperatively with doxycycline who
underwent open repair of infrarenal AAA.10
However, no clinical study has been performed to val-
idate the use of doxycycline in the management of this dis-
order, and the current trial provides the first clinical results
on the efficacy of this treatment method. Although the
patient population of this study was small, some patients
were censored at 18-month follow-up because of death or
because they required repair of the aneurysm, and there
were some nonstatistically significant differences in pre-
treatment risk factors in these two groups of patients. The
results of this study suggest that doxycycline may reduce
aneurysm growth as shown by significantly lower expan-
sion rates in the doxycycline group during the last two 
6-month intervals. Despite several censored cases, mostly
from the placebo group, the Figure depicts how the over-
all aneurysm expansion could be affected by the treatment
in a conspicuous number of cases. This effect can be
observed among patients having an aneurysm with a base-
line diameter of more than 30 mm (Figure). Further evi-
dence of its beneficial effects comes from the observation
that more patients in the placebo group required
aneurysm repair even after the end of the study.
Several studies reported an association between C
pneumoniae infection and AAA,23,24 and, thus, the effect
of doxycycline could also be partly a result of its anti-
chlamydial activity. Elevated IgA antibodies against C
pneumoniae have been reported to predict rapid expansion
of aneurysms.25 In our small study population, too few
JOURNAL OF VASCULAR SURGERY
Volume 34, Number 4 Mosorin et al 609
patients had IgA antibodies to see this effect. However,
elevated IgG titers against C pneumoniae were statistically
significantly associated with increased expansion rate in
the placebo group.
Elevated CRP concentrations as a systemic marker for
inflammation have been found to predict coronary
events,26,27 and they have also been associated with C
pneumoniae infection.28 In the current study, CRP values
3 months after discontinuation of doxycycline treatment
showed a significant decrease from the baseline values,
whereas CRP values tended to rise in the placebo group.
In conclusion, the results of this small pilot study sug-
gest that doxycycline may favorably alter the outcome of
patients with small AAAs and that this treatment can be
feasible without major adverse effect for the patients, at
least at these dosages and treatment duration. However,
because of the small size of this randomized study and of
the potentially confounding effect of pretreatment risk
factors, doxycycline-based treatment cannot be justified
only on the ground of the current results. Because of the
high prevalence of this disorder and its clinical, social, and
economic relevance, a larger study should be performed to
further investigate whether there is any place for medical
treatment of small AAAs.
We extend our sincere gratitude to Orion Pharma,
Finland, for generously providing doxycycline and placebo
tablets and for randomization, and to Mika Paldanius,
MSci, for analyzing C pneumoniae antibodies and CRP
concentrations.
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